UEEC on OTC

United Health Products, Inc.

United Health Products, Inc. is an American orthopedic company based in Mesquite, listed on OTC (UEEC).1

Price unavailable

Last updated Oct 20, 2026.

Overview

Compare with Cuprina Holdings (Cayman) LTD, Envoy Medical, Inc. or Lifeward Ltd., or pick any stock.

  • TickerUEEC on OTC1
  • IndustryOrthopedic, Prosthetic & Surgical Appliances & Supplies1
  • HeadquartersMesquite, Nevada1
  • Incorporated inNV2
  • Business address526 Commerce Circle, Ste. #120, Mesquite, Nv 890272
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Statements in this annual report on Form 10-K that are not historical facts constitute forward-looking statements which are made pursuant to the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Those factors include, among other things, those listed under “Risk Factors” and elsewhere in this annual report. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipat…3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Revenue456789$0 in 2025
0$10.0K$20.0K$30.0K$40.0K2019: $4.9K$4.9K20192020: $643$6432020−87%2021: $59$592021−91%2022: $37.5K$37.5K2022+63459%2023: $0$020232024: $0$020242025: $0$02025
Gross profit4567$0 in 2023
0$5.0K$10.0K$15.0K$20.0K2019: $3.6K$3.6K20192020: $448$4482020−88%2021: $34$342021−92%2022: $18.9K$18.9K2022+55359%2023: $0$02023
Operating income456789-$2.3M in 2025−63% since 2019
-$30.0M-$20.0M-$10.0M02019: -$6.1M-$6.1M20192020: -$14.8M-$14.8M2020+144%2021: -$29.8M-$29.8M2021+101%2022: -$2.8M-$2.8M2022−91%2023: -$2.4M-$2.4M2023−13%2024: -$2.0M-$2.0M2024−17%2025: -$2.3M-$2.3M2025+12%
Net income456789-$2.7M in 2025−60% since 2019
-$40.0M-$30.0M-$20.0M-$10.0M02019: -$6.6M-$6.6M20192020: -$15.7M-$15.7M2020+138%2021: -$30.5M-$30.5M2021+94%2022: -$1.7M-$1.7M2022−94%2023: -$2.6M-$2.6M2023+55%2024: -$2.0M-$2.0M2024−24%2025: -$2.7M-$2.7M2025+33%

Every line of the income statement as filed: the last 2 fiscal years, latest first.9

Period ending2025-12-312024-12-31
Revenues$0$0
Selling, general and administrative expenses$2.0M$1.7M
Research and development expenses$269.9K$355.9K
Total Operating Expenses$2.3M$2.0M
Loss from Operations-$2.3M-$2.0M
Interest expense-$113.3K-$32.3K
Interest expense - related party-$86.9K-$76.9K
Gain (loss) on derivative liabilities$28.3K$0
Fraud loss-$242.0K$0
Gain (loss) on settlement of debt$0$115.1K
Total Other Income (Expense)-$413.9K$5.8K
Income tax expense$0$0
Net Loss-$2.7M-$2.0M
Basic and diluted-$0.01-$0.01
Weighted average number of shares outstanding257.0M shares248.2M shares

Compare United Health Products, Inc. with another company

Corporate structure

United Health Products, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of United Health Products, Inc.

  • Wendy Beplate Irrevocable Trust Filed SCHEDULE 13D on United Health Products, Inc., latest Dec 19, 2024
  • Douglas K. Beplate Filed SC 13D/A on United Health Products, Inc., latest Dec 4, 2024
  • United Health Products, Inc. Mesquite, Nevada

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What United Health Products, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Operating-lease assets (leased space)$14.6K9 Dec 31, 2025$47.1K9 Dec 31, 2024−69.1%

Intangibles and goodwill

ItemLatestA year beforeChange
Accumulated amortization$16.2K9 Dec 31, 2025$12.2K9 Dec 31, 2024+33.3%
Finite-lived intangibles, net$24.3K9 Dec 31, 2025$28.4K9 Dec 31, 2024−14.3%

Inventory

ItemLatestA year beforeChange
Inventory, total$08 Dec 31, 2024$33.6K8 Dec 31, 2023−100.0%
Finished goods$09 Dec 31, 2025$09 Dec 31, 2024

Properties, in its own words

Since May 2023, the Company has leased approximately 1,800 square feet of office space in Mt. Laurel, New Jersey that is used as the principal executive office.

The Company is a virtual company with personnel in two states, largely working remotely.

Item 2 of the 10-K filed Apr 15, 2026.3

Leadership

Who has led United Health Products, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. William Mackey2006–2007
  2. Kelly Thomas Hickel2009
  3. Phillip David Forman2013
  4. Douglas K. Beplate2017–2021
  5. Brian David Thom2020–2025

Chair

  1. Phillip David Forman2013

President

  1. William Mackey2006
  2. Phillip David Forman2013
  3. Kristofer Heaton2020

Chief financial officer

  1. Robert Hipple2006
  2. Jan Chason2009–2011
  3. Nate Knight2019–2020
  4. Louis Schiliro2020–2021
  5. Kristofer Heaton2020

Chief operating officer

  1. Louis Schiliro2018–2021
2010201520202025
Board members and other officers (20)

Former names

  • United EcoEnergy Corp.Feb 28, 2006 to Aug 17, 20102
  • MNS EAGLE EQUITY GROUP III INCNov 23, 1999 to Jan 19, 20062

Timeline

  1. Jul 10, 20268-K Other events39
  2. Dec 22, 20258-K Entered a material agreement; New debt or obligation; Unregistered sale of shares40
  3. Jun 16, 20258-K Executive or director change41
  4. May 8, 20258-K Other events42
  5. Nov 6, 20248-K Other events43
  6. Jun 25, 20248-K Entered a material agreement44
  7. Jan 31, 20238-K Entered a material agreement; Other events45
  8. Sep 7, 20228-K Entered a material agreement; Other events46
  9. Jul 19, 20228-K Regulation FD disclosure47
  10. Jun 23, 20228-K Executive or director change; Other events48
  11. Jun 10, 20228-K Regulation FD disclosure49
  12. Apr 29, 20228-K Other events50
  13. Dec 8, 2020New chief executive Brian David Thom becomes CEO12
  14. Jun 12, 2017New chief executive Douglas K. Beplate becomes CEO13
  15. Aug 23, 2013New chief executive Phillip David Forman becomes CEO14
  16. Nov 3, 2009New chief executive Kelly Thomas Hickel becomes CEO15
  17. Mar 27, 2006New chief executive William Mackey becomes CEO16

Filings

84 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 15 major events, 17 insider forms, 2 large holders, 30 other. The latest 20:

  1. Aug 17, 2026424B3 EDGAR
  2. Aug 14, 202610-Q EDGAR
  3. Jul 10, 20268-K EDGAR
  4. May 22, 2026424B3 EDGAR
  5. May 15, 202610-Q EDGAR
  6. May 14, 2026EFFECT EDGAR
  7. May 14, 2026424B3 EDGAR
  8. May 11, 2026POS AM EDGAR
  9. Apr 15, 202610-K EDGAR
  10. Mar 31, 2026NT 10-K EDGAR
  11. Jan 30, 2026EFFECT EDGAR
  12. Jan 29, 2026CORRESP EDGAR
  13. Jan 27, 2026UPLOAD EDGAR
  14. Jan 15, 2026S-1 EDGAR
  15. Dec 22, 20258-K EDGAR
  16. Nov 14, 202510-Q EDGAR
  17. Aug 14, 202510-Q EDGAR
  18. Jun 16, 20258-K EDGAR
  19. May 8, 20258-K EDGAR
  20. May 5, 202510-Q EDGAR

The 84 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

15 open-market trades by officers, directors and large owners since October 2021: 4 buys and 11 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Apr 8, 2025Thom Brian DavidChief Executive OfficerBuy32,000$0.24$7.7KForm 4
Mar 31, 2025Thom Brian DavidChief Executive OfficerBuy18,000$0.26$4.7KForm 4
May 12, 2023Thom Brian DavidChief Executive OfficerSale300,000$0.19$57.0KForm 4
Dec 23, 2022Thom Brian DavidChief Executive OfficerSale201,400$0.21$42.3KForm 4
Dec 21, 2022Thom Brian DavidChief Executive OfficerSale98,600$0.23$22.7KForm 4
Oct 28, 2022Heaton KristoferPrincipal Financial OfficerSale5,000$0.32$1.6KForm 4
Oct 25, 2022Heaton KristoferPrincipal Financial OfficerSale4,500$0.29$1.3KForm 4
Jun 6, 2022Thom Brian DavidChief Executive OfficerSale43,945$0.47$20.7KForm 4
Jun 3, 2022Thom Brian DavidChief Executive OfficerSale56,055$0.49$27.5KForm 4
Jun 2, 2022Thom Brian DavidChief Executive OfficerSale127,100$0.51$64.8KForm 4
May 4, 2022Thom Brian DavidChief Executive OfficerBuy300,000$0.42$126.0KForm 4
Jan 3, 2022Thom Brian DavidChief Executive OfficerSale220,000$0.54$118.8KForm 4
Dec 7, 2021Thom Brian DavidChief Executive OfficerSale142,615$0.65$92.7KForm 4
Nov 22, 2021Thom Brian DavidChief Executive OfficerSale134,000$0.76$101.8KForm 4
Oct 14, 2021Thom Brian DavidChief Executive OfficerBuy27,102$0.95$25.7KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
SlateStone Wealth, LLC161,905$90.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How United Health Products, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARUnited Health Products, Inc.1
  • CIK0001096938
  • Employer ID (EIN)84-15177233
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inNevada3
  • Fiscal year endsDecember 311
  • Industry code (SIC)3842 Orthopedic, Prosthetic & Surgical Appliances & Supplies1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address526 Commerce Circle, Ste. #120, Mesquite, NV 890271
  • Phone475-755-10051
  • Shares outstanding262,685,588 as of Aug 14, 202611
  • Public float$25.2M as of Jun 30, 20253
  • AuditorMac Accounting Group & CPAs, LLP, Midvale, Utah PCAOB ID 6258; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceOct 22, 19991
  • Filings409 in all: 8-K (70), 4 (68), 10-Q (62), 10-K (21), 3 (19), 10QSB (18), NT 10-Q (17), 5 (15)1
    All 47 form types

    NT 10-K (13), 10-Q/A (8), 4/A (8), 424B3 (6), CORRESP (6), S-8 (6), UPLOAD (6), 10KSB (5), EFFECT (5), SC 13G/A (5), 1-E (4), 8-K/A (4), D (4), DEF 14A (4), DEF 14C (3), PRE 14A (3), S-1/A (3), 144 (2), DEFA14C (2), S-1 (2), S-3 (2), 10-K/A (1), 10KSB40 (1), 10SB12G (1), 10SB12G/A (1), 2-E (1), 3/A (1), 40-17G (1), N-54A (1), N-54C (1), NTN 10K (1), POS AM (1), PRE 14C (1), PREM14A (1), S-3/A (1), SC 13D (1), SC 13D/A (1), SC 13G (1), SCHEDULE 13D (1)

  • Latest filingsAnnual report (10-K) Apr 15, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Proxy statement (DEF 14A) Jul 8, 2015
    Latest 8-K (8-K) Jul 10, 2026

Risk factors and legal proceedings

The risks United Health Products, Inc. names in Item 1A of its 10-K filed Apr 15, 2026: 25 risks under these headings, as written.3

  • We are engaged in the development, sale and distribution of hemostatic gauze products to stop superficial bleeding. As we develop our business, there are numerous and varied risks, known and unknown, that may prevent us from achieving our goals. If any of these risks actually occur, our business, financial condition or results of operation may be materially adversely affected. In such case, the trading price of our common stock could decline, and investors could lose all or part of their investment.
  • RISKS RELATED TO OUR BUSINESS
  • We have a history of operating losses and we may continue to lose money in the future.
  • We can provide no assurances that the FDA will approve our Class III application for internal surgical procedures in the U.S. market for our CelluSTAT product.
  • No assurances can be given that our plans to penetrate certain market segments will be successful.
  • We can provide no assurances that ongoing discussions with potential commercial partners and acquirers will result in the occurrence of a specific transaction.
  • We will need additional financing to execute our business plan and fund operations, which may not be available.
  • No guarantee of market acceptance of our CelluSTAT Hemostatic Gauze.
  • We may be dependent upon commercial relationships to conduct our operations and implement our strategy.
  • We could experience difficulties in our supply chain.
  • We are currently dependent on one hemostatic gauze product to generate income in the future.
  • Our business may suffer if we do not attract and retain talented personnel.
The other 14 risks
  • We may not be able to adequately protect our technologies or intellectual property rights.
  • We have identified various material weaknesses in our internal control over financial reporting which could affect our ability to timely and accurately report our results of operations and financial condition. These material weaknesses may not have been fully remediated as of the filing date of this report and we cannot assure you that other material weaknesses will not be identified in the future.
  • Our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern. This could make it more difficult for us to raise funds and adversely affect our relationships with creditors, investors and suppliers.
  • RISKS RELATED TO GOVERNMENT REGULATION
  • We are subject to extensive regulation by the FDA and must comply with the regulations of the FDA (including after the potential receipt of an FDA PMA), as well as state, local and applicable international regulations. Failure to do so could harm our business.
  • The healthcare industry is subject to extensive government regulation, which can result in increased costs, delays, limits on its operating flexibility and competitive disadvantages.
  • Failure to comply with laws or government regulations could result in penalties.
  • GENERAL RISK FACTORS
  • We are subject to the reporting requirements of the federal securities laws, which can be expensive.
  • Public company compliance requirements may make it more difficult to attract and retain officers and directors.
  • There exist risks to stockholders relating to dilution: authorization of additional securities and reduction of percentage share ownership following investment.
  • Our stock price may be volatile.
  • We have not paid dividends in the past and do not expect to pay dividends in the future. Any return on investment may be limited to changes in the value of our common stock.
  • There is currently no established market for our common stock, and we cannot ensure that one will ever develop or be sustained.
  • Our common stock is deemed a “penny stock”, which may make it more difficult for our investors to sell their shares.
  • Offers or availability for sale of a substantial number of shares of our common stock may cause the price of our common stock to decline.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
    SEC EDGAROther events
  40. 40
  41. 41
  42. 42
    SEC EDGAROther events
  43. 43
    SEC EDGAROther events
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
    SEC EDGAROther events
  51. 51
  52. 52